XCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma

Momoko Yoshikawa, Kenji Tsuchihashi, Takatsugu Ishimoto, Toshifumi Yae, Takeshi Motohara, Eiji Sugihara, Nobuyuki Onishi, Takashi Masuko, Kunio Yoshizawa, Shuichi Kawashiri, Makio Mukai, Seiji Asoda, Hiromasa Kawana, Taneaki Nakagawa, Hideyuki Saya, Osamu Nagano

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

The targeting of antioxidant systems that allow stem-like cancer cells to avoid the adverse consequences of oxidative stress might be expected to improve the efficacy of cancer treatment. Here, we show that head and neck squamous cell carcinoma (HNSCC) cells that express variant isoforms of CD44 (CD44v) rely on the activity of the cystine transporter subunit xCT for control of their redox status. xCT inhibition selectively induces apoptosis in CD44v-expressing tumor cells without affecting CD44v-negative differentiated cells in the same tumor. In contrast to CD44v-expressing undifferentiated cells, CD44v-negative differentiated cells manifest EGF receptor (EGFR) activation and rely on EGFR activity for their survival. Combined treatment with inhibitors of xCT-dependent cystine transport and of EGFR resulted in a synergistic reduction of EGFR-expressing HNSCC tumor growth. Thus, xCT-targeted therapy may deplete CD44v-expressing undifferentiated HNSCC cells and concurrently sensitize the remaining differentiating cells to available treatments including EGFR-targeted therapy.

Original languageEnglish
Pages (from-to)1855-1866
Number of pages12
JournalCancer Research
Volume73
Issue number6
DOIs
Publication statusPublished - 2013 Mar 15

Fingerprint

Epidermal Growth Factor Receptor
Neoplasms
Cystine
Therapeutics
Neoplastic Stem Cells
Carcinoma, squamous cell of head and neck
Oxidation-Reduction
Protein Isoforms
Oxidative Stress
Antioxidants
Apoptosis
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

XCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. / Yoshikawa, Momoko; Tsuchihashi, Kenji; Ishimoto, Takatsugu; Yae, Toshifumi; Motohara, Takeshi; Sugihara, Eiji; Onishi, Nobuyuki; Masuko, Takashi; Yoshizawa, Kunio; Kawashiri, Shuichi; Mukai, Makio; Asoda, Seiji; Kawana, Hiromasa; Nakagawa, Taneaki; Saya, Hideyuki; Nagano, Osamu.

In: Cancer Research, Vol. 73, No. 6, 15.03.2013, p. 1855-1866.

Research output: Contribution to journalArticle

Yoshikawa, M, Tsuchihashi, K, Ishimoto, T, Yae, T, Motohara, T, Sugihara, E, Onishi, N, Masuko, T, Yoshizawa, K, Kawashiri, S, Mukai, M, Asoda, S, Kawana, H, Nakagawa, T, Saya, H & Nagano, O 2013, 'XCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma', Cancer Research, vol. 73, no. 6, pp. 1855-1866. https://doi.org/10.1158/0008-5472.CAN-12-3609-T
Yoshikawa, Momoko ; Tsuchihashi, Kenji ; Ishimoto, Takatsugu ; Yae, Toshifumi ; Motohara, Takeshi ; Sugihara, Eiji ; Onishi, Nobuyuki ; Masuko, Takashi ; Yoshizawa, Kunio ; Kawashiri, Shuichi ; Mukai, Makio ; Asoda, Seiji ; Kawana, Hiromasa ; Nakagawa, Taneaki ; Saya, Hideyuki ; Nagano, Osamu. / XCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. In: Cancer Research. 2013 ; Vol. 73, No. 6. pp. 1855-1866.
@article{e8959a50f4354820a2b7ef7c1af4ef4e,
title = "XCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma",
abstract = "The targeting of antioxidant systems that allow stem-like cancer cells to avoid the adverse consequences of oxidative stress might be expected to improve the efficacy of cancer treatment. Here, we show that head and neck squamous cell carcinoma (HNSCC) cells that express variant isoforms of CD44 (CD44v) rely on the activity of the cystine transporter subunit xCT for control of their redox status. xCT inhibition selectively induces apoptosis in CD44v-expressing tumor cells without affecting CD44v-negative differentiated cells in the same tumor. In contrast to CD44v-expressing undifferentiated cells, CD44v-negative differentiated cells manifest EGF receptor (EGFR) activation and rely on EGFR activity for their survival. Combined treatment with inhibitors of xCT-dependent cystine transport and of EGFR resulted in a synergistic reduction of EGFR-expressing HNSCC tumor growth. Thus, xCT-targeted therapy may deplete CD44v-expressing undifferentiated HNSCC cells and concurrently sensitize the remaining differentiating cells to available treatments including EGFR-targeted therapy.",
author = "Momoko Yoshikawa and Kenji Tsuchihashi and Takatsugu Ishimoto and Toshifumi Yae and Takeshi Motohara and Eiji Sugihara and Nobuyuki Onishi and Takashi Masuko and Kunio Yoshizawa and Shuichi Kawashiri and Makio Mukai and Seiji Asoda and Hiromasa Kawana and Taneaki Nakagawa and Hideyuki Saya and Osamu Nagano",
year = "2013",
month = "3",
day = "15",
doi = "10.1158/0008-5472.CAN-12-3609-T",
language = "English",
volume = "73",
pages = "1855--1866",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - XCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma

AU - Yoshikawa, Momoko

AU - Tsuchihashi, Kenji

AU - Ishimoto, Takatsugu

AU - Yae, Toshifumi

AU - Motohara, Takeshi

AU - Sugihara, Eiji

AU - Onishi, Nobuyuki

AU - Masuko, Takashi

AU - Yoshizawa, Kunio

AU - Kawashiri, Shuichi

AU - Mukai, Makio

AU - Asoda, Seiji

AU - Kawana, Hiromasa

AU - Nakagawa, Taneaki

AU - Saya, Hideyuki

AU - Nagano, Osamu

PY - 2013/3/15

Y1 - 2013/3/15

N2 - The targeting of antioxidant systems that allow stem-like cancer cells to avoid the adverse consequences of oxidative stress might be expected to improve the efficacy of cancer treatment. Here, we show that head and neck squamous cell carcinoma (HNSCC) cells that express variant isoforms of CD44 (CD44v) rely on the activity of the cystine transporter subunit xCT for control of their redox status. xCT inhibition selectively induces apoptosis in CD44v-expressing tumor cells without affecting CD44v-negative differentiated cells in the same tumor. In contrast to CD44v-expressing undifferentiated cells, CD44v-negative differentiated cells manifest EGF receptor (EGFR) activation and rely on EGFR activity for their survival. Combined treatment with inhibitors of xCT-dependent cystine transport and of EGFR resulted in a synergistic reduction of EGFR-expressing HNSCC tumor growth. Thus, xCT-targeted therapy may deplete CD44v-expressing undifferentiated HNSCC cells and concurrently sensitize the remaining differentiating cells to available treatments including EGFR-targeted therapy.

AB - The targeting of antioxidant systems that allow stem-like cancer cells to avoid the adverse consequences of oxidative stress might be expected to improve the efficacy of cancer treatment. Here, we show that head and neck squamous cell carcinoma (HNSCC) cells that express variant isoforms of CD44 (CD44v) rely on the activity of the cystine transporter subunit xCT for control of their redox status. xCT inhibition selectively induces apoptosis in CD44v-expressing tumor cells without affecting CD44v-negative differentiated cells in the same tumor. In contrast to CD44v-expressing undifferentiated cells, CD44v-negative differentiated cells manifest EGF receptor (EGFR) activation and rely on EGFR activity for their survival. Combined treatment with inhibitors of xCT-dependent cystine transport and of EGFR resulted in a synergistic reduction of EGFR-expressing HNSCC tumor growth. Thus, xCT-targeted therapy may deplete CD44v-expressing undifferentiated HNSCC cells and concurrently sensitize the remaining differentiating cells to available treatments including EGFR-targeted therapy.

UR - http://www.scopus.com/inward/record.url?scp=84875454018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875454018&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-3609-T

DO - 10.1158/0008-5472.CAN-12-3609-T

M3 - Article

C2 - 23319806

AN - SCOPUS:84875454018

VL - 73

SP - 1855

EP - 1866

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 6

ER -